Cited by 472Antiplatelet Therapy and Cardiovascular DiseasesPharmacogenetics and Drug MetabolismCoronary Interventions and Diagnostics

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.

CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events: A Systematic Review and Meta-analysis

Holmes, Michael V., Perel, Pablo, Shah, Tina, Hingorani, Aroon D., Casas, Juan P.·2011·JAMA

DOI 10.1001/jama.2011.1880

Open this paper in CoChat — free account

Abstract

CONTEXT: The US Food and Drug Administration recently recommended that CYP2C19 genotyping be considered prior to prescribing clopidogrel, but the American Heart Association and American College of Cardiologists have argued evidence is insufficient to support CYP2C19 genotype testing. OBJECTIVE: To appraise evidence on the association of CYP2C19 genotype and clopidogrel response through systematic review and meta-analysis. DATA SOURCES: PubMed and EMBASE from their inception to October 2011. STUDY SELECTION: Studies that reported clopidogrel metabolism, platelet reactivity or clinically relevant outcomes (cardiovascular disease [CVD] events and bleeding), and information on CYP2C19 genotype were included. DATA EXTRACTION: We extracted information on study design, genotyping, and disease outcomes and investigated sources of bias. RESULTS: We retrieved 32 studies of 42,016 patients reporting 3545 CVD events, 579 stent thromboses, and 1413 bleeding events. Six studies were randomized trials ("effect-modification" design) and the remaining 26 reported individuals exposed to clopidogrel ("treatment-only" design). In treatment-only analysis, individuals with 1 or more CYP2C19 alleles associated with lower enzyme activity had lower levels of active clopidogrel metabolites, less platelet inhibition, lower risk of bleeding (relative risk [RR], 0.84; 95% CI, 0.75-0.94; absolute risk reduction of 5-8 events per 1000 individuals), and higher risk of CVD events (RR, 1.18; 95% CI, 1.09-1.28; absolute risk increase of 8-12 events per 1000 individuals). However, there was evidence of small-study bias (Harbord test P = .001). When analyses were restricted to studies with 200 or more events, the point estimate was attenuated (RR, 0.97; 95% CI, 0.86-1.09). In effect-modification studies, CYP2C19 genotype was not associated with modification of the effect of clopidogrel on CVD end points or bleeding (P > .05 for interaction for both). Other limitations included selective outcome reporting and potential for genotype misclassification due to problems with the * allele nomenclature for cytochrome enzymes. CONCLUSION: Although there was an association between the CYP2C19 genotype and clopidogrel responsiveness, overall there was no significant association of genotype with cardiovascular events.

Integrity signals

Registry

Crossref · 10.1001/jama.2011.1880

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Interaction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203
Interpretation of random effects meta-analyses
Riley, R. D., Higgins, J. P. T., & Deeks, J. J. (2011) · BMJ · doi:10.1136/bmj.d549 · Cited by 2,884
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060989 · Cited by 2,819
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W. L., D, E. B. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0809171 · Cited by 2,496
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation
Sabatine, M. S., Cannon, C. P., Gibson, C. M., López-Sendón, J. L., Montalescot, G., Théroux, P., Claeys, M. J., Cools, F. J. S., Hill, K. A., Skene, A. M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050522 · Cited by 1,912
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease
Cardiogenics, Schunkert, H., the CARDIoGRAM Consortium, König, I. R., Kathiresan, S., Reilly, M. P., Assimes, T. L., Holm, H., Preuss, M., Stewart, A. F. R., et al. (2011) · Nature Genetics · doi:10.1038/ng.784 · Cited by 1,866
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study
Daemen, J., Wenaweser, P., Tsuchida, K., Abrecht, L., Vaina, S., Morger, C., Kukreja, N., Jüni, P., Sianos, G., Hellige, G., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60314-6 · Cited by 1,757
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
Simon, T., Verstuyft, C., Mary‐Krause, M., Quteineh, L., Drouet, É., Meneveau, N. F., Steg, P. G., Ferrières, J., Danchin, N., & Becquemont, L. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0808227 · Cited by 1,721
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
Shuldiner, A. R. (2009) · JAMA · doi:10.1001/jama.2009.1232 · Cited by 1,509
Genome-wide association study of blood pressure and hypertension
Levy, D., Ehret, G. B., Rice, K., Verwoert, G. C., Launer, L. J., Dehghan, A., Glazer, N. L., Morrison, A. C., Johnson, A. D., Aspelund, T., et al. (2009) · Nature Genetics · doi:10.1038/ng.384 · Cited by 1,364
Genome-wide association study identifies eight loci associated with blood pressure
Wellcome Trust Case Control Consortium, Newton-Cheh, C., Johnson, T., Gateva, V., Tobin, M. D., Bochud, M., Coin, L., Najjar, S. S., Zhao, J. H., Heath, S. C., et al. (2009) · Nature Genetics · doi:10.1038/ng.361 · Cited by 1,215
Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials
Yusuf, S. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470010097038 · Cited by 1,014
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
Collet, J., Hulot, J., Pena, A., Villard, E., Estève, J.-B., Silvain, J., Payot, L., Brugier, D., Cayla, G., Beygui, F., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61845-0 · Cited by 962
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
de Morais, S. M., Wilkinson, G. R., Blaisdell, J. A., Nakamura, K., Meyer, U., & Goldstein, J. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40694-6 · Cited by 956
Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite
Kazui, M., Nishiya, Y., Ishizuka, T., Hagihara, K., Farid, N. A., Okazaki, O., Ikeda, T., & Kurihara, A. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029132 · Cited by 836
Composite Outcomes in Randomized Trials
Freemantle, N., Calvert, M., Wood, J., Eastaugh, J., & Griffin, C. (2003) · JAMA · doi:10.1001/jama.289.19.2554 · Cited by 797
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
Wallentin, L. C., James, S. K., Storey, R. F., Armstrong, M., Barratt, B. J., Horrow, J. C., Husted, S., Katus, H. A., Steg, P. G., Shah, S. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61274-3 · Cited by 793
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
SIM, S., Risinger, C., DAHL, M., Aklillu, E., CHRISTENSEN, M., Bertilsson, L., & Ingelman‐Sundberg, M. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.10.002 · Cited by 732
Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis
Buonamici, P., Marcucci, R., Migliorini, A., Gensini, G. F., Santini, A., Paniccia, R., Moschi, G., Gori, A. M., Abbate, R., & Antoniucci, D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.094 · Cited by 655
Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement
Sibbing, D., Koch, W., Gebhard, D., Schuster, T., Braun, S., Stegherr, J., Morath, T., Schömig, A., von Beckerath, N., & Kastrati, A. (2010) · Circulation · doi:10.1161/circulationaha.109.885194 · Cited by 586
Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents
Trenk, D., Hochholzer, W., Fromm, M. F., Chialda, L., Pahl, A. M., Valina, C. M., Stratz, C., Schmiebusch, P., Bestehorn, H.-P., Büttner, H. J., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.12.056 · Cited by 537
Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment
Paré, G., Mehta, S. R., Yusuf, S., Anand, S. S., Connolly, S. J., Hirsh, J., Simonsen, K. L., Bhatt, D. L., Fox, K. A. A., & Eikelboom, J. W. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008410 · Cited by 534
Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials
González, I. F., Permanyer-Miralda, G., Domingo‐Salvany, A., Busse, J. W., Heels‐Ansdell, D., Montori, V. M., Akl, E. A., Bryant, D., Alonso‐Coello, P., Alonso, J., et al. (2007) · BMJ · doi:10.1136/bmj.39136.682083.ae · Cited by 484
Paraoxonase-1 is a major determinant of clopidogrel efficacy
Bouman, H. J., Schömig, E., van Werkum, J. W., Velder, J., Hackeng, C. M., Hirschhäuser, C., Waldmann, C. M., Schmalz, H., ten Berg, J. M., & Taubert, D. (2010) · Nature Medicine · doi:10.1038/nm.2281 · Cited by 466
DRUG REACTIONS, ENZYMES, AND BIOCHEMICAL GENETICS
Motulsky, A. G. (1957) · JAMA · doi:10.1001/jama.1957.72980250010016 · Cited by 449
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
Sibbing, D., Stegherr, J., Latz, W., Koch, W., Mehilli, J., Dörrler, K., Morath, T., Schömig, A., Kastrati, A., & von Beckerath, N. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehp041 · Cited by 417
CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet™ systematic review and meta-analysis
Sanderson, S., Emery, J. D., & Higgins, J. P. T. (2005) · Genetics in Medicine · doi:10.1097/01.gim.0000153664.65759.cf · Cited by 361
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”
Holmes, D. R., DEHMER, G. J., Kaul, S., Leifer, D., O’Gara, P. T., & Stein, C. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.013 · Cited by 356
Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome.
Campo, G., Parrinello, G., Ferraresi, P., Lunghi, B., Tebaldi, M., Miccoli, M., Marchesini, J., Bernardi, F., Ferrari, R., & Valgimigli, M. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.12.047 · Cited by 351
Random-Effects Meta-Analyses Are Not Always Conservative
Poole, C., & Greenland, S. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010035 · Cited by 338
Nature's randomised trials
Hingorani, A. D., & Humphries, S. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67767-7 · Cited by 277
Self-citation
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis
Bauer, T., Bouman, H. J., van Werkum, J. W., Ford, N. F., ten Berg, J. M., & Taubert, D. (2011) · BMJ · doi:10.1136/bmj.d4588 · Cited by 263
Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients
Giusti, B., Gori, A. M., Marcucci, R., Saracini, C., Sestini, I., Paniccia, R., Valente, S., Antoniucci, D., Abbate, R., & Gensini, G. F. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f1b2be · Cited by 230
International HapMap Project
National Cancer Institute (2020) · Definitions · doi:10.32388/f4olbl · Cited by 227
Relation of Cytochrome P450 2C19 Loss-of-Function Polymorphism to Occurrence of Drug-Eluting Coronary Stent Thrombosis
Giusti, B., Gori, A. M., Marcucci, R., Saracini, C., Sestini, I., Paniccia, R., Buonamici, P., Antoniucci, D., Abbate, R., & Gensini, G. F. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.11.048 · Cited by 224
Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome
Frère, C., Cuisset, T., Morange, P., Quilici, J., Camoin‐Jau, L., Saut, N., Faille, D., Lambert, M., Juhan-Vague, I., Bonnet, J., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.11.065 · Cited by 210
Clopidogrel Resistance
Wiviott, S. D., & Antman, E. M. (2004) · Circulation · doi:10.1161/01.cir.0000134701.40946.30 · Cited by 200
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting
Sibbing, D., Koch, W., Maßberg, S., Byrne, R. A., Mehilli, J., Schulz, S., Mayer, K., Bernlochner, I., Schömig, A., & Kastrati, A. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr155 · Cited by 186
Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events
Tiroch, K. A., Sibbing, D., Koch, W., Roosen-Runge, T., Mehilli, J., Schömig, A., & Kastrati, A. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.06.039 · Cited by 166
CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study
Harmsze, A. M., van Werkum, J. W., ten Berg, J. M., Zwart, B., Bouman, H. J., Breet, N. J., Hof, A. W. J. V. ’., Ruven, H. J. T., Hackeng, C. M., Klungel, O. H., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq321 · Cited by 159
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.06.024 · Cited by 151
The Relative Efficacy and Safety of Clopidogrel in Women and Men
Berger, J. S., Bhatt, D. L., Cannon, C. P., Chen, Z., Jiang, L., Jones, J. B., Mehta, S. R., Sabatine, M. S., Steinhubl, S. R., Topol, E. J., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.05.074 · Cited by 145
The clopidogrel in unstable angina to prevent recurrent events trial investigators: effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
(2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00542-6 · Cited by 138
Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials
Yusuf, S. (1991) · JAMA · doi:10.1001/jama.266.1.93 · Cited by 129
Can We Override Clopidogrel Resistance?
Peña, A., Collet, J., Hulot, J., Silvain, J., Barthélémy, O., Beygui, F., Funck‐Brentano, C., & Montalescot, G. (2009) · Circulation · doi:10.1161/circulationaha.108.857722 · Cited by 121
Fulfilling the Promise of Personalized Medicine? Systematic Review and Field Synopsis of Pharmacogenetic Studies
Holmes, M. V., Shah, T., Vickery, C., Smeeth, L. L., Hingorani, A. D., & Casas, J. P. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007960 · Cited by 103
Self-citation
The Star-Allele Nomenclature: Retooling for Translational Genomics
Robarge, J., Li, L., Desta, Z., Nguyen, A., & Flockhart, D. A. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100284 · Cited by 101
Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy
Yamamoto, K., Hokimoto, S., Chitose, T., Morita, K., Ono, T., Kaikita, K., Tsujita, K., Abe, T., Deguchi, M., Miyagawa, H., et al. (2010) · Journal of Cardiology · doi:10.1016/j.jjcc.2010.10.007 · Cited by 100
Coexisting Polymorphisms of P2Y12 and CYP2C19 Genes as a Risk Factor for Persistent Platelet Activation With Clopidogrel
Małek, Ł. A., Kisiel, B. M., Śpiewak, M., Grabowski, M., Filipiak, K. J., Kostrzewa, G., Huczek, Z., Płoski, R., & Opolski, G. (2008) · Circulation Journal · doi:10.1253/circj.72.1165 · Cited by 94
Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents
Oh, I., Park, K. W., Kang, S., Park, J. J., Na, S. H., Kang, H., Koo, B., Jeong, Y., Hwang, J., Kwak, C. H., et al. (2011) · Heart · doi:10.1136/hrt.2011.227272 · Cited by 90
Impact of Cytochrome P450 2C19*2 Polymorphism on Intra-Stent Thrombus After Drug-Eluting Stent Implantation in Japanese Patients Receiving Clopidogrel
Sawada, T., Shinke, T., Shite, J., Honjo, T., Haraguchi, Y., Nishio, R., Shinohara, M., Toh, R., Ishida, T., Kawamori, H., et al. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0525 · Cited by 74
Combined influence of proton‐pump inhibitors, calcium‐channel blockers and CYP2C19*2 on on‐treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention
Harmsze, A. M., van Werkum, J. W., Souverein, P. C., Breet, N. J., Bouman, H. J., Hackeng, C. M., Ruven, H. J. T., ten Berg, J. M., Klungel, O. H., de Boer, A., et al. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04483.x · Cited by 46
International HapMap Project
Dubitzky, W., Olaf Wolkenhauer, A., Cho, K.-H., & Yokota, H. (2013) · Springer eBooks · doi:10.1007/978-1-4419-9863-7_100710 · Cited by 44
Genetic Polymorphism ofCYP2C19Gene in the Stanislas Cohort. A link with Inflammation
Thiebault, C., Berrahmoune, H., Thompson, A., Bastien, B., Droesch, S., Siest, G., Foernzler, D., & Visvikis‐Siest, S. (2008) · Annals of Human Genetics · doi:10.1111/j.1469-1809.2007.00417.x · Cited by 39
Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention
Ono, T., Kaikita, K., Hokimoto, S., Iwashita, S., Yamamoto, K., Miyazaki, Y., Horio, E., Sato, K., Tsujita, K., Abe, T., et al. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.07.028 · Cited by 34
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis
Stockman, J. A. (2012) · Yearbook of Pediatrics · doi:10.1016/j.yped.2012.03.021 · Cited by 28
Cytochrome P450 2C19 Polymorphism, Suboptimal Reperfusion and All-Cause Mortality in Patients with Acute Myocardial Infarction
Małek, Ł. A., Przyłuski, J., Śpiewak, M., Kłopotowski, M. M., Kostrzewa, G., Kruk, M. B. P., Płoski, R., Witkowski, A., & Rużyłło, W. (2010) · Cardiology · doi:10.1159/000320093 · Cited by 27
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and anti-depressants
Buckley, P. F. (2007) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)70611-x · Cited by 15
PharmGKB: The Pharmacogenomics Knowledgebase
Barbarino, J. M., Whirl‐Carrillo, M., Klein, T. E., & Altman, R. B. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386882-4.00014-1 · Cited by 12
Monday, 29 August 2011
(2011) · European Heart Journal · doi:10.1093/eurheartj/ehr323 · Cited by 9
The Value of Combining CYP2C19*2 Polymorphism with Classic Risk Factors in Prediction of Clinical Prognosis in Acute Coronary Syndrome Patients
Yan, S., Chen, M., Li, Q., Liu, X., Peng, Y., Chai, H., Xu, Y., Wei, J., & Huang, D. (2011) · Cardiology · doi:10.1159/000329048 · Cited by 6
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
Mega, J. L., Close, S. L., & Wiviott, S. D. (2009) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2009.02.023 · Cited by 6
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
Gersh, B. J. (2010) · Yearbook of Cardiology · doi:10.1016/s0145-4145(09)79743-6 · Cited by 5
Sunday, 28 August 2011
Žaliaduonytė, D., Janėnaitė, J., Marcinkevičienė, J. E., Mizariene, Tamakauskas, V., Kviesulaitis, V., & Vaskelyte, J. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr322 · Cited by 4
Poster session 4
Radišauskas, R., Bernotienė, G., Bacevičienė, M., Šidlauskienė, D., & Bernotas, K. (2011) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/1741826711407011 · Cited by 3

Flagged first, then by citations

Sorted by citations

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“, 2011), associationwith clopidogrel metabolic concentration and platelet reactivity responsiveness but no overall associationwith cardiovascular events in another one (Holmes et al., 2011), while the most recent study, which analyzed 16 clinical studies, confirmed significant associations with major cardiovascular en…”
Result
2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)
Jneid, H. M., Anderson, J. L., Wright, R. S., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Lincoff, A. M., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318256f1e0 · Cited by 1,091
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
Scott, S. A., Sangkuhl, K., Stein, C. M., Hulot, J., Mega, J. L., Roden, D. M., Klein, T. E., Sabatine, M. S., Johnson, J. A., & Shuldiner, A. R. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.105 · Cited by 962
2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.014 · Cited by 967
Implementing genomic medicine in the clinic: the future is here
Manolio, T. A., Chisholm, R. L., Ozenberger, B., Roden, D. M., Williams, M. S., Wilson, R., Bick, D. P., Böttinger, E. P., Brilliant, M. H., Eng, C., et al. (2013) · Genetics in Medicine · doi:10.1038/gim.2012.157 · Cited by 580

See all 472

Authors: Holmes, M. V., Perel, P., Shah, T., Hingorani, A. D., & Casas, J. P.
Affiliations: University College London (GB)
Northwestern University (US)
ORCID: Holmes, Michael V.
Perel, Pablo
Shah, Tina
Hingorani, Aroon D.
Casas, Juan P.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2011-12-28
Volume: 306
Issue: 24
Pages: 2704
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.2011.1880
OpenAlex: W2119186881
Cited by: 472
References: 70
Citations by year: 2026: 10 · 2025: 10 · 2024: 7 · 2023: 13 · 2022: 18 · 2021: 22 · 2020: 19 · 2019: 27 · 2018: 23 · 2017: 25 · 2016: 36 · 2015: 46 · 2014: 53 · 2013: 89 · 2012: 70
FWCI: 47.48
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute for Health and Care Research (RP-PG-0407-10314)
British Heart Foundation (FS05/125)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Keywords: CYP2C19 genotype, clopidogrel, clopidogrel response, platelet function, platelet aggregation inhibition, cardiovascular events, bleeding risk, stent thrombosis, genotype testing, pharmacogenetics, small-study bias, effect modification, clopidogrel resistance, clopidogrel hypersensitivity, clopidogrel metabolite
MeSH terms: Clopidogrel, Aryl Hydrocarbon Hydroxylases, Cardiovascular Diseases, Genotype, Hemorrhage, Humans, Platelet Aggregation, Platelet Aggregation Inhibitors, Platelet Function Tests, Risk, Thrombosis, Ticlopidine, Angioplasty, Balloon, Coronary, Randomized Controlled Trials as Topic, Cytochrome P-450 CYP2C19

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events: A Systematic Review and Meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks